The CSL Centenary Fellowships for early-mid career medical researchers are high-value awards available to Australians who wish to continue a career in medical research in Australia. Two individual five-year $1.25 million fellowships are awarded each calendar year.
This $25 million program was established by CSL Limited in its Centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.
The 2020 Fellows will be announced on Thursday 10 October, 2019.
CSL Limited is a global specialty biotechnology company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions.
Two Australian scientists have each been awarded AUD$1.25
million CSL Centenary Fellowships over five years to improve treatments for two
of the world’s biggest health challenges: malaria and cancer. The Fellowships
will be presented in Perth at the Australian Academy for Health and Medical
Research Gala Dinner on 10 October.
Dr Kamala Thriemer will use her $1.25 million CSL
Centenary Fellowship to develop and optimise treatment programs against vivax
malaria in SE Asia and the Horn of Africa.
Vivax malaria is the second largest cause of malaria deaths and is hard to treat as the parasite can hide in the liver and re-emerge months later. Her studies have shown that as few as one in ten patients successfully complete the long course of treatment.
Kamala is a public health researcher at the Menzies School
of Health Research in Darwin.
Dan Thomas has developed new ways to identify a cancer’s weakness and target it with personalised treatment. He’s already treating acute myeloid leukaemia patients in Adelaide.
His $1.25 million
CSL Centenary Fellowship will facilitate his return from Stanford University to
the South Australian Health and Medical Research Institute (SAHMRI) and The
University of Adelaide.
Daniel began his academic career with a PhD in haematology
from the University of Adelaide.
Is long term memory stored in DNA, and what does it mean for Alzheimer’s?
Changing the odds from one in 10 for older leukaemia patients
Scientists available for interview.
Two Brisbane scientists have each been awarded an AUD$1.25 million, five-year CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease.
Professor Geoff Faulkner and Associate Professor Steven Lane are the inaugural Fellows in a $25 million program established by CSL in its centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.
Professor Geoff Faulkner from the University of Queensland thinks long-term memory might be stored in our brain’s DNA and he’ll test his theory in brains affected by Alzheimer’s.
Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak, with only 10 per cent surviving beyond one year as their cancer adapts to weather the storm of standard chemotherapy treatments. Steven wants to change that outlook.
Two Australian scientists have each been awarded an AUD$1.25 million, five-year CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease.
Professor Geoff Faulkner and Associate Professor Steven Lane are the inaugural Fellows in a $25 million program established by CSL in its centenary year to support Australia’s best and brightest biomedical researchers—fostering excellence in medical research by supporting mid-career scientists to pursue world-class research at an Australian institution.
Geoff Faulkner is testing a bold idea— he thinks long-term memory might be stored in our brain’s DNA. If he’s right, it will revolutionise both our understanding of life’s blueprint and how we manage diseases like schizophrenia and Alzheimer’s.
There’s DNA in every human cell called ‘junk’ or ‘non-coding’ DNA because our bodies don’t use it to generate proteins, the building blocks of life.
The strange thing is, this DNA makes up over 98 per cent of our genome. Surely it must do something. The question is: what?
Geoff Faulkner has been studying this question for years with his team from the MRI-UQ. Now, working with the Queensland Brain Institute (QBI), Geoff’s inaugural CSL Centenary Fellowship will help him delve deeper, using brains bequeathed by Alzheimer’s patients.
Leukaemia is one of Australia’s deadliest types of cancer. However, as Steven Lane knows, it’s not just one type—it’s hundreds of different types, each with its own genetic fingerprint.
This variation means some types of leukaemia are treatable, whereas others quickly develop resistance. Today, 85 per cent of children with leukaemia can be cured, but the outlook for patients over 60 is bleak—only 10 per cent survive beyond one year.
Steven wants to change that outlook. Together with his team at the QIMR Berghofer Medical Research Institute in Brisbane he has developed the capacity to rapidly profile the genetics of leukaemia types and model them in the lab.
CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia.
The announcement was made last night by CSL’s Chief Executive Officer, Mr Paul Perreault, at the CSL Centenary Celebration Gala. Mr Perreault also announced that the highly respected molecular biologist, Professor Ashley Dunn, will Chair the Selection Committee.
All of our usual services are available including our training forums and workshops, which are now delivered online.
Our team are all working from home and can consult/train/mentor/write via phone, Zoom, Teams, Skype etc
Upcoming training sessions:
Media and communication masterclass:
Practice interviews. Key messages. Tricky questions. How to ensure your research is reported accurately.
Sarah's structure of the course, specific insight and understanding of science, her contacts and common mistakes made in communication were great and furthered my skills in this area.
Anonymous - Sydney Jan 2020
2020-01-28T15:04:28+11:00
Anonymous - Sydney Jan 2020
Sarah's structure of the course, specific insight and understanding of science, her contacts and common mistakes made in communication were great and furthered my skills in this area.
This is one of the best science communication courses I have ever encountered. It teaches all research to think out of box and really simplify their research in lay man's language. I will highly recommend this to anyone looking to learn more about science communication.
Shwathy Ramesh
2020-02-24T09:29:55+11:00
Shwathy Ramesh
This is one of the best science communication courses I have ever encountered. It teaches all research to think out of box and really simplify their research in lay man's language. I will highly recommend this to anyone looking to learn more about science communication.
The CSL Centenary Fellowships for early-mid career medical researchers are high-value awards available to Australians who wish to continue a career in medical research in Australia. Two individual five-year $1.25 million fellowships are awarded each calendar year.
CSL Limited Media Release
Geoff Faulkner is testing a bold idea— he thinks long-term memory might be stored in our brain’s DNA. If he’s right, it will revolutionise both our understanding of life’s blueprint and how we manage diseases like schizophrenia and Alzheimer’s.
Leukaemia is one of Australia’s deadliest types of cancer. However, as Steven Lane knows, it’s not just one type—it’s hundreds of different types, each with its own genetic fingerprint.
CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia.
All of our usual services are available including our 
